1. U.S. sales of Merck’s cancer immunotherapy drug Keytruda missed analysts’ estimates for the first three months of 2016. Keytruda brought in revenue of $133 million for the first quarter of 2016, compared to consensus estimates of $158 million.
2. Vanda Pharmaceuticals spent more than $29 million on television ads for its drug Hetlioz, which treats a circadian rhythm disorder present in people who are blind. The campaign may be specifically targeting family and friends of people with the disorder. (Stat)
3. The Centers for Disease Control and Prevention are warning parents of preschoolers with attention deficit hyperactivity disorder that they should try behavioral therapy before seeking drugs. (WaPo)
4. An FDA advisory panel unanimously voted to recommend mandatory training for opioid-prescribing doctors. The training is aimed at teaching doctors how to use opioid-based painkillers sparingly. (WSJ)
5. Two new studies published in Health Affairs say that the U.S. is paying more for cancer drugs than other countries but with little added benefit. The findings also suggest there is little downward pressure on the price of oral cancer drugs in the U.S. (Morning Consult)